Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
Authors' conclusion
Patients with rheumatoid arthritis may have different levels of risk of diabetes depending on the treatment options.
Study context
- Population
- Adults with RA without diabetes, Chang Gung Research Database546 developed diabetes
- Participants
- 5,530 adults
- Exposure
- DMARD treatment periods vs methotrexate (MTX) monotherapy periods
- Outcome
- New-onset diabetes (HbA1c ≥7% during follow-up)
Methodological detailstime-varying exposure in 1-month units
- Time-varying exposure in 1-month units
Main finding
As reported in the abstract
New-onset diabetes
Each group vs MTX monotherapyHazard ratio (95% CI)
bDMARDs
0.51(0.32–0.83)
MTX combination
0.50(0.32–0.78)
Other cDMARDs
0.56(0.37–0.84)
- Overall incidence of diabetes 2001–2018: 546 participants
- 9.87%
Observational data: associations, not effects.
Further findings
Diabetes risk, individual drug analysis: hydroxychloroquine
| HR (95% CI) | ||
|---|---|---|
| Hydroxychloroquine | 0.52 (0.42–0.65) | |
| 0.512Hazard ratio (log scale) |
Diabetes risk, individual drug analysis: tumour necrosis factor-α inhibitors
| HR (95% CI) | ||
|---|---|---|
| Tumour necrosis factor-α inhibitorsTended to be protective | 0.69 (0.46–1.03) | |
| 0.512Hazard ratio (log scale) |
Original publication
Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis. RMD Open. Published 17 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →